Similarly, the NORA trial (NCT04816838) confirmed that neoadjuvant osimertinib plus chemotherapy significantly improved the MPR compared with chemotherapy alone in patients with operable, stage IA-IIIB EGFR-mutant NSCLC[28,29]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.